Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

Commitments and Contingencies - Additional Information (Details)			3 Months Ended		9 Months Ended
	Aug. 17, 2020 USD ($)	Apr. 10, 2015 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2020 USD ($) MilestonePayment	Sep. 30, 2020 EUR (€) MilestonePayment	Jun. 30, 2021 USD ($)	Dec. 20, 2020 USD ($)	Aug. 31, 2020 USD ($)	Aug. 18, 2020 USD ($)	Jun. 30, 2017 USD ($)
Purchase Commitment
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable					$ 10,840,000
Alkermes Plc \| Amendment to Purchase and Sale Agreement
Supply Commitment [Line Items]
Milestone development earn-out consideration payable									$ 5,000,000	$ 2,500,000
Payment for one-time non-refundable and non-creditable fee	$ 285,000
Collaborative arrangements milestone payments upon achievement of regulatory and sales milestones					12,500,000
Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Scenario Forecast
Supply Commitment [Line Items]
Milestone development earn-out consideration payable							$ 1,440,000	$ 1,060,000
U.S \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones											$ 5,000,000
European \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones											$ 3,000,000
Maximum \| Executive Officer
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreements					$ 1,327,000
Recro \| Alkermes Transaction
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 140,000,000
Recro \| Alkermes Transaction \| Regulatory Approval and Net Sales Milestones
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 50,000,000
Collaborative arrangements, milestone payments period		7 years
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, First Component
Supply Commitment [Line Items]
Business acquisition contingent consideration, first milestone payment				$ 5,000,000
Business acquisition contingent consideration possible milestone payments			$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Third Component
Supply Commitment [Line Items]
Minimum milestone payments percentage					60.00%	60.00%
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage					30.00%	30.00%
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due, Following Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments					$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due, Beginning on First Anniversary of Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments					$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| MilestonePayment					7	7
Business acquisition, contingent consideration, equal annual milestone payments					$ 6,400,000
Recro \| Minimum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage					10.00%	10.00%
Recro \| Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition, contingent consideration, milestone payments due period following regulatory approval					180 days	180 days
Recro \| Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage					12.00%	12.00%
Recro \| Dexmedetomidine License Agreement
Supply Commitment [Line Items]
Contingent milestone payments, maximum					$ 24,033,000	€ 20,500,000
Amount of royalty payments due or payable					$ 0
Recro \| Dexmedetomidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments					10.00%	10.00%
Recro \| Dexmedetomidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments					20.00%	20.00%
Recro \| Fadolmidine License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable					$ 0
Additional contingent milestones payment					$ 14,304,000	€ 12,200,000
Recro \| Fadolmidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments					10.00%	10.00%
Recro \| Fadolmidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments					15.00%	15.00%